3Tomasz W,Glinka G.Cephalosporin antibiotics and prodrugs thereof[P].US6599893B2,2003-07-29. 被引量：1
4Wehe T,Pletz MW.Antimicrubial treatment of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia:Current and future options[J].Int J Antimicrob Agents,2010,36(5):391-400. 被引量：1
5Noel GJ,Bush K,Baqchi P,et al.A randomized,doubleblind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections[J].Clin Infect Dis,2008,46(5):656-658. 被引量：1
6Schmitt-Hoffmann A,Nyman L,Roos B,et al.Muhipledose pharmacokinetics and safety of a novel broad spectrum cephalosporin (BAL5788) in healthy volunteers[J].Antimicrob Agents Chemother,2004,48(7):2576-2580. 被引量：1
7Parish D,Scheinfeld N.Ceftsroline fosamil,a cephalosporin derivative for the potential treatment of MRSA infection[J].Curt Opin Invest Drugs,2008,9(2):201-209. 被引量：1
8Talbot GH,Thye D,Das A,et al.Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections[J].Antimicrob Agents Chemother,2007,51(10):3612-3616. 被引量：1
9Sader HS,Fritsche TR,Jones RN.Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus[J].Antimicrob Agents Chemother,2008,52(3):1153-1155. 被引量：1
10Mushtaq S,Warner M,Ge Y,et al.In vitro activity of eeftaroline (PPI-0903M,T-91825) against bacteria with defined resistance mechanisms and phenotypes[J].J Antimicrob Chemother,2007,60(2):300-311. 被引量：1
